$13.09
7.21% yesterday
Nasdaq, Oct 31, 09:00 pm CET
ISIN
US30233G1004
Symbol
EYPT

EyePoint Pharmaceuticals, Inc. Stock price

$13.09
-1.15 8.08% 1M
+6.27 91.94% 6M
+5.64 75.70% YTD
+1.33 11.31% 1Y
+7.69 142.41% 3Y
+9.19 235.64% 5Y
-25.51 66.09% 10Y
-45.51 77.66% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
+0.88 7.21%
ISIN
US30233G1004
Symbol
EYPT
Industry

Key metrics

Basic
Market capitalization
$841.6m
Enterprise Value
$585.9m
Net debt
positive
Cash
$255.7m
Shares outstanding
68.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
16.2 | 22.5
EV/Sales
11.3 | 15.7
EV/FCF
negative
P/B
3.4
Financial Health
Equity Ratio
80.4%
Return on Equity
-38.9%
ROCE
-70.6%
ROIC
-738.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$51.9m | $37.4m
EBITDA
$-187.1m | $-237.9m
EBIT
$-189.1m | $-231.7m
Net Income
$-175.4m | $-214.4m
Free Cash Flow
$-194.0m
Growth (TTM | estimate)
Revenue
3.0% | -13.6%
EBITDA
-91.5% | -64.9%
EBIT
-91.7% | -58.9%
Net Income
-102.0% | -63.8%
Free Cash Flow
-105.6%
Margin (TTM | estimate)
Gross
95.1%
EBITDA
-360.6% | -636.6%
EBIT
-364.3%
Net
-337.9% | -573.6%
Free Cash Flow
-373.9%
More
EPS
$-2.5
FCF per Share
$-2.8
Short interest
13.9%
Employees
165
Rev per Employee
$260.0k
Show more

Is EyePoint Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

EyePoint Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

Buy
95%
Hold
5%

Financial data from EyePoint Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
52 52
3% 3%
100%
- Direct Costs 2.52 2.52
42% 42%
5%
49 49
7% 7%
95%
- Selling and Administrative Expenses 55 55
10% 10%
107%
- Research and Development Expense 183 183
94% 94%
353%
-187 -187
91% 91%
-361%
- Depreciation and Amortization 1.91 1.91
115% 115%
4%
EBIT (Operating Income) EBIT -189 -189
92% 92%
-364%
Net Profit -175 -175
102% 102%
-338%

In millions USD.

Don't miss a Thing! We will send you all news about EyePoint Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EyePoint Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to report its third quarter 2025 financial re...
Neutral
GlobeNewsWire
16 days ago
WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in ...
Neutral
GlobeNewsWire
17 days ago
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $12.00 per share and, ...
More EyePoint Pharmaceuticals, Inc. News

Company Profile

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Duker
Employees 165
Founded 1987
Website eyepointpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today